The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Open accessAbstract
BACKGROUND: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of nintedanib in patients with ILD associated with systemic sclerosis. Patients who had systemic sclerosis with an onset of the first non-Raynaud's symptom within the past 7 years and a high-resolution computed tomographic scan that showed fibrosis affecting at least 10% of the lungs were randomly assigned, in a 1:1 ratio, to receive 150 mg of nintedanib, administered orally twice daily, or placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed over a 52-week period. Key secondary end points were absolute changes from baseline in the modified Rodnan skin score and in the total score on the St. George's Respiratory Questionnaire (SGRQ) at week 52. RESULTS: A total of 576 patients received at least one dose of nintedanib or placebo; 51.9% had diffuse cutaneous systemic sclerosis, and 48.4% were receiving mycophenolate at baseline. In the primary end-point analysis, the adjusted annual rate of change in FVC was -52.4 ml per year in the nintedanib group and -93.3 ml per year in the placebo group (difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P = 0.04). Sensitivity analyses based on multiple imputation for missing data yielded P values for the primary end point ranging from 0.06 to 0.10. The change from baseline in the modified Rodnan skin score and the total score on the SGRQ at week 52 did not differ significantly between the trial groups, with differences of -0.21 (95% CI, -0.94 to 0.53; P = 0.58) and 1.69 (95% CI, -0.73 to 4.12 [not adjusted for multiple comparisons]), respectively. Diarrhea, the most common adverse event, was reported in 75.7% of the patients in the nintedanib group and in 31.6% of those in the placebo group. CONCLUSIONS: Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other manifestations of systemic sclerosis. The adverse-event profile of nintedanib observed in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were more common with nintedanib than with placebo. (Funded by Boehringer Ingelheim; SENSCIS ClinicalTrials.gov number, NCT02597933.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This observation is therefore in accordance with recent clinical trials showing that antifibrotic therapies are effective in progressive fibrotic interstitial lung diseases other than IPF [20,26,27].”
In the citing paper
“nintedanib has also now been approved for systemic sclerosis (SSc)-associated ILD (SSc-ILD), based on the positive outcome of Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial (Distler et al., 2019).”
From Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies (2023) · cites this paper as Distler et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationvan den Hoogen, F. H. J., Khanna, D., Fransen, J., Johnson, S. R., Baron, M. G., Tyndall, A., Matucci‐Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204424 · Cited by 2,881
Self-citationThe St George's Respiratory Questionnaire
Jones, P., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,729
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationInterstitial Lung Disease in Systemic Sclerosis
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J. C., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,249
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J. G., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,077
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citationWalker, U. A., Tyndall, A., Czirják, L., Denton, C. P., Farge, D., Kowal‐Bielecka, O., Müller‐Ladner, U., Bocelli‐Tyndall, C., & Matucci‐Cerinic, M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062901 · Cited by 927
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,000
Keret, S., Henig, I. J., Zuckerman, T., Kaly, L., Shouval, A., Awisat, A., Rosner, I., Rozenbaum, M., Boulman, N., Lazar, A. D., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead457 · Cited by 29
Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment
Pugashetti, J. V., & Lee, J. S. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1782218 · Cited by 29
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
Valenzuela, C., Torrisi, S. E., Kahn, N. C., Quaresma, M., Stowasser, S., & Kreuter, M. (2020) · Respiratory Research · doi:10.1186/s12931-019-1269-6 · Cited by 29
Self-citationMaher, T. M., Assassi, S., Azuma, A., Cottin, V., Hoffmann-Vold, A.-M., Kreuter, M., Oldham, J. M., Richeldi, L., Valenzuela, C., Wijsenbeek, M. S., et al. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001580 · Cited by 28
Self-citationImaging in the diagnosis and management of fibrosing interstitial lung diseases
Lederer, C., Storman, M., Tárnoki, Á. D., Tárnoki, D. L., Margaritopoulos, G. A., & Prosch, H. (2024) · Breathe · doi:10.1183/20734735.0006-2024 · Cited by 29
Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis
Volkmann, E. R., Denton, C. P., Kolb, M. R. J., Wijsenbeek-Lourens, M. S., Emson, C. L., Hudson, K. J., Amatucci, A. J., Distler, O., Allanore, Y., & Khanna, D. (2024) · European Respiratory Review · doi:10.1183/16000617.0015-2024 · Cited by 28
Self-citationSaketkoo, L. A., Scholand, M. B., Lammi, M. R., & Russell, A. (2020) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198320904178 · Cited by 28
Campochiaro, C., Luca, G. D. D., Lazzaroni, M. G., Zanatta, E., Bosello, S. L., Santis, M. D., Cariddi, A., Bruni, C., Selmi, C. F., Gremese, E., et al. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa136 · Cited by 28
Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
Meier, C. F., Freiburghaus, K., Bovet, C., Gote-Schniering, J., Allanore, Y., Distler, O., Nakas, C. T., & Maurer, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-78951-6 · Cited by 30
Self-citationHoffmann‐Vold, A., Maher, T. M., Philpot, E. E., Ashrafzadeh, A., & Distler, O. (2021) · ERJ Open Research · doi:10.1183/23120541.00235-2020 · Cited by 28
Self-citationInterstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP)
Hino, T., Lee, K. S., Yoo, H., Han, J., Franks, T. J., & Hatabu, H. (2021) · European Journal of Radiology Open · doi:10.1016/j.ejro.2021.100336 · Cited by 28
López-Matencio, J. M. S., Gómez, M., Vicente‐Rabaneda, E. F., González-Gay, M. Á., Ancochea, J., & Castañeda, S. (2021) · Pharmaceuticals · doi:10.3390/ph14080819 · Cited by 29
Papadimitriou, T. I., van Caam, A., van der Kraan, P. M., & Thurlings, R. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020316 · Cited by 30
Zamparelli, S. S., Sanduzzi, A., & Bocchino, M. (2023) · Diagnostics · doi:10.3390/diagnostics13142437 · Cited by 30
Zhang, Y., Fu, J., Li, C., Chang, Y., Li, X., Cheng, H., Qiu, Y., Shao, M., Han, Y., Feng, D., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04961-y · Cited by 29
Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK
Dixon, G., Hague, S., Mulholland, S., Adamali, H. I., Khin, A. M. N., Thould, H., Connon, R., Minnis, P., Murtagh, E., Khan, F., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00529-2023 · Cited by 30
Lescoat, A., Cavalin, C., Ehrlich, R. I., Cazalets, C., Ballerie, A., Belhomme, N., Coiffier, G., Riquier, M. D. S., Rosental, P., HACHULLA, E., et al. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30038-4 · Cited by 28
Lencz, T., PhD, Cornblatt, B., PhD, Bilder, A. R. M., & PhD (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4274 · Cited by 28
The Effect of Nintedanib on T-Cell Activation, Subsets and Functions
Ubieta, K., Thomas, M. J., & Wollin, L. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s288369 · Cited by 29
A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease
Khor, Y. H., Saravanan, K., Holland, A. E., Lee, J. Y. T., Ryerson, C. J., McDonald, C. F., & Goh, N. S. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-86326-8 · Cited by 27
Inspiratory muscle training in interstitial lung disease: a systematic scoping review
Hoffman, M. (2021) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210089 · Cited by 28
Nambiar, A. M., Walker, C. M., & Sparks, J. A. (2021) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666211039771 · Cited by 27
Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
Copeland, C. R., & LANCASTER, L. H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.743977 · Cited by 28
Future Treatment Options in Systemic Sclerosis—Potential Targets and Ongoing Clinical Trials
Bohdziewicz, A., Pawlik, K. K., Maciejewska, M., Sikora, M., Alda-Malicka, R., Czuwara, J., & Rudnicka, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051310 · Cited by 27
Swigris, J. J., Bushnell, D. M., Rohr, K., Mueller, H., Baldwin, M., & Inoue, Y. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001167 · Cited by 27
Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis
Khanna, S. A., Nance, J. W., & Suliman, S. A. (2022) · Current Rheumatology Reports · doi:10.1007/s11926-022-01067-5 · Cited by 27
Shi, H., Deng, L., Zhou, Y., Yu, H., Huang, X. X., Chen, M., Yang, L., & Dong, J. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116691 · Cited by 27
Lee, J. K., Ahn, Y., Noh, H. N., Lee, S. M., Yoo, B., Lee, C., Kim, Y., Hong, S., Ahn, S. M., & Kim, H. C. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01212-z · Cited by 29
Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
Mirsaeidi, M. S., Barletta, P., & Glassberg, M. K. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00248 · Cited by 28
Nevskaya, T., Zheng, B., Baxter, C. A., Ramey, D. R., Pope, J. E., & Baron, M. G. (2019) · Rheumatology · doi:10.1093/rheumatology/kez529 · Cited by 27
Jiang, J., Wang, F., Luo, A., Lin, S., Feng, X., Yan, W., Shi, Y., Zhang, Q., Gu, X., Cui, G., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00767 · Cited by 27
ANCA Status or Clinical Phenotype — What Counts More?
Windpessl, M., Bettac, E. L., Gauckler, P., Shin, J. I., Geetha, D., & Kronbichler, A. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-01002-0 · Cited by 27
Santos, C. S., Antolín, S. C., Lorenzo, J. D. L. C., Garay, C. L., Morales, C. M., de Miguel, E. B., Guerrero, M. R., Herránz, L. S., & Álvarez, E. D. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152366 · Cited by 26
Delaney, L., Alabed, S., Maiter, A., Salehi, M., Goodlad, M., Shah, H. Y., Checkley, E. W., Matthews, S., Kamil, M., Evans, O., et al. (2024) · Radiology · doi:10.1148/radiol.240016 · Cited by 26
Moore, I., Wrobel, J. P., Rhodes, J. E., Lin, Q., Webster, S. E., Jo, H. E., Troy, L. K., Grainge, C., Glaspole, I., Corte, T. J., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01297-2 · Cited by 27
Nathan, S. D., Pastré, J., Ksovreli, I., Barnett, S. D., King, C. S., Aryal, S., Ahmad, K., Fukuda, C. Y., Ramalingam, V. S., & Chung, J. H. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620968496 · Cited by 26
Chen, C., Lin, H.-C., Wang, Y., Wang, C., Lin, Y. S., & Lai, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251636 · Cited by 27
Mackintosh, J. A., Pietsch, M., Lutzky, V. P., Enever, D., Bancroft, S., Apte, S. H., Tan, M. E., Yerkovich, S. T., Dickinson, J. L., Pickett, H. A., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001127 · Cited by 30
Plasma Metabolomic Profiling Reveals Four Possibly Disrupted Mechanisms in Systemic Sclerosis
Bögl, T., Mlynek, F., Himmelsbach, M., Sepp, N. T., Buchberger, W. W., & Geroldinger‐Simić, M. (2022) · Biomedicines · doi:10.3390/biomedicines10030607 · Cited by 26
Takeuchi, T., Hayashi, M., Tamita, T., Nomura, Y., Kojima, N., Mitani, A., Takeda, T., Hitaka, K., Kato, Y., Kamitani, M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00613 · Cited by 26
Assessment of disease outcome measures in systemic sclerosis
Lafyatis, R., & Valenzi, E. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00803-6 · Cited by 26
Plasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis
Sari, E., He, C., & Margaroli, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911443 · Cited by 28
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region
Lescoat, A., Huscher, D., Schoof, N., Airó, P., de Vries-Bouwstra, J. K., Riemekasten, G., HACHULLA, E., Doria, A., Rosato, E., Hunzelmann, N., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac576 · Cited by 26
Self-citationJee, A. S., Stewart, I. D., Youssef, P. P., Adelstein, S., Lai, D., Hua, S., Stevens, W., Proudman, S., Ngian, G., Glaspole, I., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42491 · Cited by 29
Type 2 cytokines and scleroderma interstitial lung disease
Pellicano, C., Vantaggio, L., Colalillo, A., Pocino, K., Basile, V., Marino, M., Basile, U., & Rosato, E. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01125-x · Cited by 26
High-Resolution CT Scan Fibrotic Patterns in Stage IV Pulmonary Sarcoidosis
Obi, O. N., Alqalyoobi, S., Maddipati, V., Lower, E. E., & Baughman, R. P. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.10.021 · Cited by 28
Central Role of CT in Management of Pulmonary Fibrosis
Chae, K. J., Hwang, H. J., Achcar, R. D., Cooley, J. C., Humphries, S. M., Kligerman, S. J., & Lynch, D. A. (2024) · Radiographics · doi:10.1148/rg.230165 · Cited by 26
Kuwana, M., Ogura, T., Makino, S., Homma, S. A., Kondoh, Y., Saito, A., Ugai, H., Gahlemann, M., Takehara, K., & Azuma, A. (2020) · Modern Rheumatology · doi:10.1080/14397595.2020.1751402 · Cited by 26
Self-citationProgressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies
Wongkarnjana, A., Scallan, C. J., & Kolb, M. R. J. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000712 · Cited by 26
Li, Q., Wallace, L., Patnaik, P., Alves, M., Gahlemann, M., KOHLBRENNER, V. M., Raabe, C., Wang, J. R., & Garry, E. M. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa547 · Cited by 26
Self-citationPathological Insight into 5-HT2B Receptor Activation in Fibrosing Interstitial Lung Diseases
Löfdahl, A., Tornling, G., Wigén, J., Larsson‐Callerfelt, A., Wenglén, C., & Westergren‐Thorsson, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010225 · Cited by 27
New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025
Santos, C. S., & Galdo, F. D. (2025) · RMD Open · doi:10.1136/rmdopen-2025-005776 · Cited by 25
Emerging therapies for the treatment of systemic sclerosis
Distler, J. H. W., Kuwana, M., Assassi, S., & Denton, C. P. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01294-x · Cited by 26
Self-citationChallenges in systemic sclerosis trial design
Denton, C. P. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.09.019 · Cited by 25
An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis
McMahan, Z. H., & Volkmann, E. R. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1793960 · Cited by 25
Deterding, R. R., Griese, M., Deutsch, G. H., Warburton, D., DeBoer, E. M., Cunningham, S., Clément, A., Schwerk, N., Flaherty, K. R., Brown, K. K., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00805-2020 · Cited by 28
Self-citationSuzuki, Y., Mori, K., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01587-3 · Cited by 26
Cutolo, M., Gotelli, E., Montagna, P., Tardito, S., Paolino, S., Pizzorni, C., Sulli, A., Smith, V. M., & Soldano, S. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02555-2 · Cited by 25
E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects
Sharma, S., Watanabe, T., Nishimoto, T., Takihara, T., Mlakar, L., Nguyen, X.-X., Sanderson, M., Su, Y., Chambers, R. A., & Feghali‐Bostwick, C. A. (2021) · JCI Insight · doi:10.1172/jci.insight.144935 · Cited by 25
Birnhuber, A., Jandl, K., Biasin, V., Fließer, E., Valzano, F., Marsh, L. M., Krolczik, C., Olschewski, A., Wilhelm, J., Toller, W. G., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02347-2021 · Cited by 25
Kreuter, M., Hoffmann‐Vold, A., Matucci‐Cerinic, M., Saketkoo, L. A., Highland, K. B., Wilson, H., Alves, M., Erhardt, E. M., Schoof, N., & Maher, T. M. (2022) · Rheumatology · doi:10.1093/rheumatology/keac325 · Cited by 25
Self-citationNintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: A single-centre study
Singh, P. K., Behera, D., Gupta, S. S., Deep, A., Priyadarshini, S., & Padhan, P. (2022) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715221103402 · Cited by 25
Boutel, M., Boutou, A., Pitsiou, G., Garyfallos, A., & Dimitroulas, T. (2023) · Diagnostics · doi:10.3390/diagnostics13071221 · Cited by 26
Immune-mediated lung diseases: A narrative review
Sweis, J. J. G., Sweis, N. W. G., Alnaimat, F., Jansz, J., Liao, T. E., Alsakaty, A., Azam, A., Elmergawy, H., Hanson, H. A., Ascoli, C., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1160755 · Cited by 25
Richter, P., Cardoneanu, A., Dima, N., Bratoiu, I., Rezuș, C., Burlui, A., Costin, D., Macovei, L. A., & Rezuş, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119388 · Cited by 27
Wang, X., Gadhave, D. G., Chauhan, G., & Gupta, V. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105233 · Cited by 25
Roennow, A., Sauvé, M., Welling, J., Riggs, R. J., Kennedy, A. T., Galetti, I., Brown, E., Leite, C. C., González, A. V., Guiraud, A. P. P., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-039473 · Cited by 25
Self-citationFoeldvari, I., Torok, K. S., Antón, J., Blakley, M., Constantin, T., Cutolo, M., Denton, C. P., Fligelstone, K., Hinrichs, B., Li, S. C., et al. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2298354 · Cited by 24
Shlobin, O. A., Shen, E., Wort, S. J., Piccari, L., Scandurra, J., Hassoun, P. M., Nikkho, S. M., & Nathan, S. D. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12310 · Cited by 25
Deneuville, L., Mageau, A., Debray, M., Sacré, K., Costedoat-Chalumeau, N., HACHULLA, E., Uzunhan, Y., Tallec, E. L., Cadranel, J. L., Marchand-Adam, S., et al. (2024) · Respirology · doi:10.1111/resp.14703 · Cited by 25
Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies
Asano, Y., & Varga, J. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.12.007 · Cited by 24
Khedoe, P. P. S. J., Marges, E. R., Hiemstra, P. S., Ninaber, M. K., & Geelhoed, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01990 · Cited by 24
Avdeev, S. N., Chikina, S. Y., Tyurin, I. E., Belevskiy, А. S., Terpigorev, S. A., Ananyeva, L. P., VIZEL, A. A., Болдина, М. В., Демко, И. В., Викторович, Л. И., et al. (2021) · PULMONOLOGIYA · doi:10.18093/0869-0189-2021-31-4-505-510 · Cited by 24
Assassi, S., Distler, O., Allanore, Y., Ogura, T., Varga, J., Vettori, S., Crestani, B., Voß, F., Alves, M., Stowasser, S., et al. (2022) · ACR Open Rheumatology · doi:10.1002/acr2.11483 · Cited by 24
Self-citationManagement of progressive pulmonary fibrosis associated with connective tissue disease
Molina‐Molina, M., Castellvi, I., Valenzuela, C., Ramírez, J., Portal, J. A. R., Franquet, T., & Narváez, J. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2107508 · Cited by 24
Hoffmann‐Vold, A., Brunborg, C., Airó, P., Ananyeva, L. P., Czirják, L., Guiducci, S., HACHULLA, E., Li, M., Mihai, C., Riemekasten, G., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.09.044 · Cited by 24
Self-citationHamberg, V., Sohrabian, A., Volkmann, E. R., Wildt, M., Löfdahl, A., Wuttge, D. M., Hesselstrand, R., Dellgren, G., Westergren‐Thorsson, G., Rönnelid, J., et al. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-023-03141-4 · Cited by 24
Petelytska, L., Bonomi, F., Cannistrà, C., Fiorentini, E., Peretti, S., Torracchi, S., Bernardini, P., Coccia, C., Luca, R. D., Economou, A., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2023-003426 · Cited by 26
Self-citationDefining genetic risk factors for scleroderma-associated interstitial lung disease
Stock, C. J. W., Lauretis, A. D., Visca, D., Daccord, C., Kokosi, M. A., Kouranos, V., Margaritopoulos, G. A., George, P. M., Molyneaux, P. L., Nihtyanova, S. I., et al. (2020) · Clinical Rheumatology · doi:10.1007/s10067-019-04922-6 · Cited by 24
Self-citationNew insights into the treatment of CTD-ILD
Wells, A. U. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00567-x · Cited by 24
Tanguy, J., Pommerolle, L., Garrido, C., Kolb, M. R. J., Bonniaud, P., Goirand, F., & Bellaye, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179316 · Cited by 26
Murdaca, G., Caprioli, S., Tonacci, A., Billeci, L., Greco, M., Negrini, S., Cittadini, G., Zentilin, P., Spagnolo, E. V., & Gangemi, S. (2021) · Diagnostics · doi:10.3390/diagnostics11101880 · Cited by 24
A new era in the treatment of progressive fibrosing interstitial lung diseases
Denis, A., Tsiri, P., Guiot, J., & Τzouvelekis, Α. (2025) · Breathe · doi:10.1183/20734735.0259-2024 · Cited by 30
Nonspecific Interstitial Pneumonia
Teoh, A. K. Y., & Corte, T. J. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1708499 · Cited by 23
The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis
Bruni, C., Guignabert, C., Manetti, M., Matucci‐Cerinic, M., & Humbert, M. J. C. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30356-8 · Cited by 23
Pulmonary arterial hypertension in systemic sclerosis
Lechartier, B., & Humbert, M. J. C. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104062 · Cited by 23
Watanabe, S., Kase, K., Saeki, K., Ohkura, N., Murata, A., Waseda, Y., Takato, H., Ichikawa, Y., Yasui, M., & Kasahara, K. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106689 · Cited by 23
Jandali, B., Salazar, G. A., Hudson, M., Fritzler, M. J., Lyons, M. A., Estrada-Y-Martin, R. M., Charles, J., Terracina, K. A., Mayes, M. D., & Assassi, S. (2022) · ACR Open Rheumatology · doi:10.1002/acr2.11398 · Cited by 23
Self-citationMouawad, J. E., Sharma, S., Renaud, L., Pilewski, J. M., Nadig, S. N., & Feghali‐Bostwick, C. A. (2022) · Rheumatology · doi:10.1093/rheumatology/keac411 · Cited by 23
Ninagawa, K., Kato, M., Tsuneta, S., Ishizaka, S., Ujiie, H., Hisada, R., Kono, M., Fujieda, Y., Ito, Y. M., & Atsumi, T. (2022) · Rheumatology · doi:10.1093/rheumatology/keac674 · Cited by 23
Ceribelli, A., Tonutti, A., Isailovic, N., Santis, M. D., & Selmi, C. F. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1068402 · Cited by 23
New therapeutic approaches against pulmonary fibrosis
Yu, D., Yu, X., Gou, T., Tong, R., Xu, C. S., Chen, L., Zhong, L., & Shi, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106592 · Cited by 24
Diagnosis and management of primary heart involvement in systemic sclerosis
Luca, G. D. D., Matucci‐Cerinic, M., & Mavrogeni, S. I. (2023) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000990 · Cited by 23
New trajectories in the treatment of interstitial lung disease
Morisset, J., & Lee, J. S. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000600 · Cited by 23
Galdo, F. D., Hartley, C., & Allanore, Y. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30007-2 · Cited by 23
Hoffmann‐Vold, A., & Molberg, Ø. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000741 · Cited by 24
Lescoat, A., Murphy, S. L., Roofeh, D., Pauling, J. D., Hughes, M., Sandler, R. D., Zimmermann, F., Wessel, R., Townsend, W. A., Chung, L. S., et al. (2020) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198320961967 · Cited by 24
Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews
Hoffmann‐Vold, A., Bendstrup, E. M., Dimitroulas, T., Hesselstrand, R., Morais, A., Peltomaa, R., Smith, V. M., Welling, J., Vonk, M. C., & Wuyts, W. A. (2021) · Rheumatology · doi:10.1093/rheumatology/keab154 · Cited by 23
Kreuter, M., Galdo, F. D., Miede, C., Khanna, D., Wuyts, W. A., Hummers, L. K., Alves, M., Schoof, N., Stock, C., & Allanore, Y. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02710-9 · Cited by 23
Self-citationHuang, T., Kuo, C., Chen, C., Tseng, Y., Wu, C., & Lin, S. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01530-6 · Cited by 24
Metadata
- Authors
- Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., Clerisme-Beaty, E., Stowasser, S., Tetzlaff, K., Kuwana, M., & Maher, T. M.
- Affiliations
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-27
- Volume
- 380
- Issue
- 26
- Pages
- 2518-2528
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945521814
- Cited by
- 1,647
- References
- 36
- Citations by year
- 2026: 139 · 2025: 203 · 2024: 215 · 2023: 231 · 2022: 243 · 2021: 299 · 2020: 247 · 2019: 68
- FWCI
- 157.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, systemic sclerosis, systemic sclerosis-associated interstitial lung disease, tyrosine kinase inhibitors, antifibrotic therapy, forced vital capacity decline, pulmonary fibrosis, diffuse cutaneous systemic sclerosis, skin involvement, quality of life, diarrhea, adverse events, mycophenolate, modified Rodnan skin score, St George's Respiratory Questionnaire
- MeSH terms
- Administration, Oral, Adult, Diarrhea, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Scleroderma, Systemic, Vital Capacity, Lung Diseases, Interstitial, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
